- Home
- RARE vs INSW Comparison
RARE vs INSW Comparison
Compare RARE & INSW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RARE | INSW |
|---|---|---|
| Founded | 2010 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Semiconductors |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 2.6B |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | RARE | INSW |
|---|---|---|
| Price | $33.60 | $50.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 1 |
| Target Price | ★ $85.20 | $48.00 |
| AVG Volume (30 Days) | ★ 1.4M | 527.1K |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | ★ 5.69% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 4.39 |
| Revenue | $630,598,000.00 | ★ $770,036,000.00 |
| Revenue This Year | $19.65 | N/A |
| Revenue Next Year | $23.65 | $7.43 |
| P/E Ratio | ★ N/A | $11.73 |
| Revenue Growth | ★ 20.63 | N/A |
| 52 Week Low | $25.81 | $27.20 |
| 52 Week High | $50.00 | $55.18 |
Technical Indicators
Market Signals| Indicator | RARE | INSW |
|---|---|---|
| Relative Strength Index (RSI) | 52.82 | 46.40 |
| Support Level | $32.06 | $52.65 |
| Resistance Level | $34.77 | $55.18 |
| Average True Range (ATR) | 1.40 | 1.47 |
| MACD | 0.08 | -0.52 |
| Stochastic Oscillator | 66.67 | 12.29 |
Price Performance
Historical ComparisonAbout RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About INSW International Seaways Inc.
International Seaways Inc owns and operates a fleet of oceangoing vessels engaged in the transportation of crude oil and petroleum products. The company's vessel operations are organized into two segments: Crude Tankers and Product Carriers. The fleet consists of ULCC, VLCC, Suezmax, Aframax, and Panamax crude tankers, as well as LR1, LR2, and MR product carriers.